5 Years Since MannKind Received FDA Approval For Afrezza Doubts Swirl [Seeking Alpha]
MannKind Corporation (MNKD)
Last mannkind corporation earnings: 2/25 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.mannkindcorp.com/press-releases
Company Research
Source: Seeking Alpha
5 Years Since MannKind Received FDA Approval For Afrezza Doubts Swirl When entrepreneur and philanthropist Alfred Mann established what would come to be known as MannKind Corporation ( MNKD Source: MannKind 2004 10K After two Complete Response letters and additional clinical studies the FDA approved Afrezza on June 27, 2014. When Sanofi ( SNY worldwide rights Five years since receiving FDA approval, Sanofi returning Afrezza to MannKind, the passing of Alfred Mann, and two CEOs, Afrezza revenue is negligible and MannKind's finances are disturbing. Management has tried several marketing strategies, all have not produced meaning results. Afrezza may not be economically viable, marketing strategies inappropriate, or both. Change is nee
Read more
Impact Snapshot
Event Time:
MNKD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNKD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNKD alerts
High impacting MannKind Corporation news events
Weekly update
A roundup of the hottest topics
MNKD
News
- MannKind Co. (NASDAQ: MNKD) was upgraded by analysts at Mizuho to a "strong-buy" rating.MarketBeat
- MannKind Co. (NASDAQ: MNKD) is now covered by analysts at Mizuho. They set an "outperform" rating and a $12.00 price target on the stock.MarketBeat
- MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment OptionsGlobeNewswire
- MannKind Co. (NASDAQ: MNKD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22 [Yahoo! Finance]Yahoo! Finance
MNKD
Earnings
- 2/26/25 - Beat
MNKD
Sec Filings
- 4/4/25 - Form 4
- 4/1/25 - Form ARS
- 4/1/25 - Form DEFA14A
- MNKD's page on the SEC website